In this analysis, we focused only on the 60 mg kg−1 dose of dulanermin, which has been previously demonstrated to provide optimal anti-tumour activity in pre-clinical models and resulted in tumour regressions (Ashkenazi et al, 1999; Kelley et al, 2001), and evaluated additional time points around 24 h, where significant serum caspase 3/7 increases were observed. Here, CASP3 is linked to neoplasm.